Gordon J. Freeman

Harvard University — United States

Medicine · Health Sciences

174h-index129.3kcitations1.1kworks4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(531), Immune Cell Function and Interaction(332), Immunotherapy and Immune Responses(215), CAR-T cell therapy research(182), T-cell and B-cell Immunology(165)

Publications1.1k total

Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy
Cell Research·2025Open Access
Targeted destruction of VISTA boosts anti-tumor immunotherapy
Cell Research·2025Open Access
Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy
Blood·2025Open Access
Overcoming microbiome-dependent resistance to cancer immunotherapy 2210
The Journal of Immunology·2025Open Access
Exposed phosphatidylserine is a non-classical inhibitory molecule during CD8 T cell exhaustion 2323
The Journal of Immunology·2025Open Access
4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial
The Oncologist·2025Open Access
2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial
Annals of Oncology·2025
PD-1 is requisite for skin TRM cell formation and specification by TGFβ
Nature Immunology·2025· 10 citedOpen Access
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
The Journal of Experimental Medicine·2025· 5 citedOpen Access
Author Correction: ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
Nature Communications·2025Open Access
Abstract 770: ccRCC metastasis rewires tumor microenvironment to increase immunosuppression and fibrosis
Cancer Research·2025
Abstract 3229: Investigating the transcriptomic signature of HHLA2-mediated suppression of NK cell activity
Cancer Research·2025
Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease
Nature·2025· 36 citedOpen Access
RGMb drives macrophage infiltration to aggravate kidney disease
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
Abstract A014: Blocking the HHLA2 immune checkpoint alters transcriptomic signature in specific subsets of NK cells
Cancer Research·2025
796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial
Laboratory Investigation·2025Open Access
Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.
Journal of Clinical Oncology·2025
Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings
mAbs·2024· 2 citedOpen Access
Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
Blood·2024· 1 cited
Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
Blood·2024· 1 citedOpen Access
page 1 of 55Next →

Frequent Co-authors

Arlene H. Sharpe(19), Rafi Ahmed(8), Scott J. Rodig(6), Glenn Dranoff(6), Vijay K. Kuchroo(5), E. John Wherry(4), Baogong Zhu(4), Bjoern Chapuy(4), Margaret A. Shipp(4), Mary Keir(3), Manish J. Butte(3), Azra H. Ligon(3), Philippe Armand(3), Julia A. Brown(3), W. Nicholas Haining(3), Edward Greenfield(3), Kwok‐Kin Wong(3), Spencer C. Liang(3), Yvette Latchman(3), Donna Neuberg(3)